Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$0.51 USD
-0.02 (-3.13%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $0.50 -0.01 (-2.15%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
Atara Biotherapeutics, Inc. [ATRA]
Reports for Purchase
Showing records 61 - 80 ( 108 total )
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 - Multiple Catalysts in 2021; tabcel Launch Expected in 2022
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tab-Cel Regulatory Application Timeline Still Intact; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bayer Strategic Collaboration Inked on CAR-T Assets; Raising PT to $31
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bayer Collaboration a Testament to ATRA''s T-cell Prowess; Also ASH Update
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 - tab-cel Program Update Following FDA Discussions
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tab-cel Phase 3 ALLELE Trial Hits Mark; 3Q20 Financials; Raising PT to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ATA188 Seems to Improve Long-Term Multiple Sclerosis Disability; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
tab-cel Demonstrates Efficacy in EBVDriven Lymphoproliferative Diseases
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sustainable Improvements in Late-Stage Multiple Sclerosis
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T